Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cidara Thera (CDTX)

Cidara Thera (CDTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 65,427
  • Shares Outstanding, K 90,619
  • Annual Sales, $ 64,290 K
  • Annual Income, $ -29,800 K
  • 60-Month Beta 0.98
  • Price/Sales 1.06
  • Price/Cash Flow N/A
  • Price/Book 9.26
Trade CDTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.39
  • Most Recent Earnings $-0.09 on 11/02/23
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 423.67% ( -2.32%)
  • Historical Volatility 107.48%
  • IV Percentile 70%
  • IV Rank 28.27%
  • IV High 1,384.86% on 02/09/24
  • IV Low 44.77% on 11/15/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 372
  • Volume Avg (30-Day) 167
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 3,875
  • Open Int (30-Day) 2,875

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year 0.03
  • Growth Rate Est. (year over year) -333.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6820 +5.87%
on 03/19/24
1.2200 -40.82%
on 04/03/24
+0.0285 (+4.11%)
since 03/18/24
3-Month
0.6250 +15.52%
on 02/01/24
1.2200 -40.82%
on 04/03/24
-0.0280 (-3.73%)
since 01/18/24
52-Week
0.5930 +21.75%
on 11/17/23
1.4800 -51.22%
on 05/23/23
-0.4080 (-36.11%)
since 04/18/23

Most Recent Stories

More News
Cidara Therapeutics: Q3 Earnings Snapshot

Cidara Therapeutics: Q3 Earnings Snapshot

CDTX : 0.7220 (-0.03%)
Cidara Therapeutics: Q2 Earnings Snapshot

Cidara Therapeutics: Q2 Earnings Snapshot

CDTX : 0.7220 (-0.03%)
Cidara Therapeutics: Q1 Earnings Snapshot

Cidara Therapeutics: Q1 Earnings Snapshot

CDTX : 0.7220 (-0.03%)
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of 19.63% and 27.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

MRUS : 40.47 (-1.41%)
CDTX : 0.7220 (-0.03%)
Are Options Traders Betting on a Big Move in Cidara (CDTX) Stock?

Investors need to pay close attention to Cidara (CDTX) stock based on the movements in the options market lately.

CDTX : 0.7220 (-0.03%)
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -1,800% and 45.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

CDTX : 0.7220 (-0.03%)
CRMD : 5.42 (-0.37%)
Cidara Therapeutics: Q4 Earnings Snapshot

Cidara Therapeutics: Q4 Earnings Snapshot

CDTX : 0.7220 (-0.03%)
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis

Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment...

CDTX : 0.7220 (-0.03%)
Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Top Estimates

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.01% and 1.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

HZNP : 116.30 (+0.04%)
CDTX : 0.7220 (-0.03%)
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee voted favorably 14 to 1 that...

CDTX : 0.7220 (-0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company...

See More

Key Turning Points

3rd Resistance Point 0.7777
2nd Resistance Point 0.7638
1st Resistance Point 0.7429
Last Price 0.7220
1st Support Level 0.7081
2nd Support Level 0.6942
3rd Support Level 0.6733

See More

52-Week High 1.4800
Fibonacci 61.8% 1.1412
Fibonacci 50% 1.0365
Fibonacci 38.2% 0.9318
Last Price 0.7220
52-Week Low 0.5930

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar